CN101386640A - 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 - Google Patents
金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 Download PDFInfo
- Publication number
- CN101386640A CN101386640A CNA2008100589773A CN200810058977A CN101386640A CN 101386640 A CN101386640 A CN 101386640A CN A2008100589773 A CNA2008100589773 A CN A2008100589773A CN 200810058977 A CN200810058977 A CN 200810058977A CN 101386640 A CN101386640 A CN 101386640A
- Authority
- CN
- China
- Prior art keywords
- cathelicidin
- lysine
- phenylalanine
- variant
- methionin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000741302 Bungarus fasciatus Cathelicidin-related antimicrobial peptide Bf-CRAMP Proteins 0.000 title claims abstract description 17
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 5
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 4
- 108060001132 cathelicidin Proteins 0.000 claims description 6
- 102000014509 cathelicidin Human genes 0.000 claims description 6
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000272081 Bungarus fasciatus Species 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 5
- 239000004472 Lysine Substances 0.000 abstract description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 239000004474 valine Substances 0.000 abstract description 3
- 229940121657 clinical drug Drugs 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 230000002147 killing effect Effects 0.000 abstract 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 13
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 241000270295 Serpentes Species 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 9
- 241000272060 Elapidae Species 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000003998 snake venom Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000270296 Boa constrictor Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241001530038 Pantherophis obsoletus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 101710099833 Venom protein Proteins 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 108010078256 antimicrobial peptide IB-367 Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960003716 cilastatin sodium Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108010062940 pexiganan Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用,属于生物医学领域。金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15是一种直链多肽,含有15个氨基酸残基,分子量1939.47Da,等电点12.05。cathelicidin-BF15全序列为:缬氨酸-赖氨酸-精氨酸-苯丙氨酸-赖氨酸-赖氨酸-苯丙氨酸-苯丙氨酸-精氨酸-赖氨酸-亮氨酸-赖氨酸-赖氨酸-丝氨酸-缬氨酸。cathelicidin-BF15具有强烈的杀菌作用,对多种临床耐药菌有非常强的杀灭作用,此外具有结构简单,人工合成方便和广谱抗菌等有益特点。
Description
技术领域:
本发明提供一种金环蛇(Bungarus fasciatus)抗菌肽cathelicidin—BF变异体cathelicidin—BF15及其应用,属于生物医学技术领域。
背景技术:
Cathelicidin是一个具有多功能的抗菌肽家族,目前仅在哺乳类、鸟类和鱼类中有发现。Cathelicidin具有广谱的抗菌活性,不仅对革兰氏阳性菌、革兰氏阴性菌、某些真菌以及病毒具有非常强的杀菌活性,而且对许多临床耐药细菌同样具有作用。除此之外,cathelicidin还具有许多其他生物学活性,如对多种免疫细胞具有趋化作用、诱导肥大细胞脱粒和组织胺释放、调节巨噬细胞转录、促进伤口愈合、诱导血管发生、诱导变异细胞系细胞凋亡和淋巴细胞活化等。由于具有如此众多的活性,cathelicidin一直是国际上研究的热点。针对cathelicidin的药用开发则蕴含着巨大的临床治疗药物制备价值。
随着青霉素等传统抗生素的大规模和不恰当使用,微生物对传统抗生素产生了越来越强的耐受性,在临床上已经出现了大量能够完全耐受青霉素等传统抗生素的微生物,已有的抗生素对这些病原微生物无能为力。抗菌肽是一种新型的抗微生物多肽,大多数抗菌肽分子量小于10000Da,带正电,富含疏水碱基,能够形成两亲性的结构。抗菌肽的杀菌机制主要是通过静电相互作用吸引并结合到带负电的细菌细胞膜表面,进一步在细菌细胞膜上形成跨膜的孔洞,导致细菌细胞内容物的外泄,从而导致细菌细胞的死亡。而传统抗生素主要是作用于细菌细胞内的一些酶类。正是由于作用方式的不同,抗菌肽介导的杀菌作用远远快于传统抗生素,并且不易使细菌产生耐受性。除此之外,越来越多的文献报道表明抗菌肽还具有其他的杀菌机制,如抑制细菌细胞壁合成、改变细菌细胞质膜抑制隔膜形成、激活自溶素、抑制细胞内酶活性、抑制DNA、RNA和蛋白质的合成等。
目前,国外有许多公司正在进行抗菌肽的研究开发,已有多种抗菌肽进入临床试验阶段。如来源于人lactoferrin的hLF-1—1用于治疗骨髓干细胞移植相关的感染,已进入临床II期。来源于非洲爪蟾magainin的MSI-78对糖尿病患者的足部溃疡有显著疗效且副作用小,已进入临床III期试验阶段。来源于猪protegrin的IB-367用于治疗肿瘤患者口腔溃疡,已进入临床I期试验。除此之外,一些用于伤口愈合,内毒素感染,肿瘤,病毒感染的抗菌肽也已进入临床试验阶段。
在中国的传统中药和民族医药中,许多蛇类被作为药材而得到广泛的应用,如乌稍蛇,蟒蛇,蝮蛇,金环蛇,银环蛇,眼镜蛇,五步蛇等。蛇全身均可入药,蛇肉具有强壮神经、延年益寿功效,可治疗病后体弱、风痹麻木、关节疼痛等症。蛇胆具有祛风、清热、化痰、明目的功效,主治小儿疳积、痔疮肿痛。蛇胆汁乙醇溶液能有效治疗角膜炎、角膜溃疡、角膜斑翳。以蛇胆汁、川贝母、杏仁为主要原料制成的“蛇胆川贝液”,是目前临床使用方便、疗效显著的止咳祛痰良药,蛇蜕具有祛风定惊、杀虫、退翳消肿、清热解毒的功能,可治目翳、疮疖、痔漏、痄腮、疟疾、小儿惊痫、疥癣、瘰疬等症。蛇毒是目前国际药材市场上十分昂贵的珍奇药材,利用蝮蛇毒制成的注射液,具有明显的抗癌、抗血凝作用。
与此同时,传统中药药物成分的复杂性及其炮制方法的局限性造成药物活性成分不能更好的发挥作用,因而从这些传统药物中寻找特定的活性单体化合物是中药现代化的重要内容之一。迄今为止,国内外学者已经从蛇毒中分离出大量生物活性蛋白及多肽,其中的许多活性多肽具有很好的药物开发前景。
金环蛇属于眼镜蛇科环蛇属,是具有前沟牙的毒蛇,广泛分布于中国南方各省及东南亚各国。目前关于金环蛇蛇毒蛋白,各种蛋白酶及抑制剂有大量报道,但是关于金环蛇蛇毒中抗菌肽的研究还没有报道。
发明人将本发明的金环蛇抗菌肽cathelicidin-BF变异体cathelicidin—BF15全序列氨基酸结构经NCBI蛋白质数据库进行搜寻比对,未发现有任何相同多肽。发明人将本发明的金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15编码基因经NCBI基因数据库进行搜寻比对,未发现有任何相同基因。
发明内容:
本发明的目的是基于上述理论研究和现有技术基础,提供一种具有强烈的抗菌活性的金环蛇抗菌肽cathelicidin-BF变异体cathelicidin—BF15及其应用。
为了实现本发明的目的,本发明提供了如下技术方案:
金环蛇cathelicidin-BF15是金环蛇抗菌肽cathelicidin—BF的一种变异体。cathelicidin-BF15是一种直链多肽,含有15个氨基酸残基,分子量1939.47Da,等电点12.05。cathelicidin-BF15全序列为:缬氨酸—赖氨酸—精氨酸—苯丙氨酸—赖氨酸—赖氨酸—苯丙氨酸—苯丙氨酸—精氨酸—赖氨酸—亮氨酸—赖氨酸—赖氨酸—丝氨酸—缬氨酸。
金环蛇cathelicidin-BF15的制备方法:
根据分离纯化所得金环蛇抗菌肽cathelicidin—BF氨基酸序列,利用蛋白组学方法设计cathelicidin—BF的突变体cathelicidin—BF15。用自动多肽合成仪(433A,Applied Biosystems)合成其全序列,通过HPLC反相柱层析脱盐纯化,并确定其纯度大于95%。用基质辅助激光解析电离飞行时间质谱(MALDI-TOF)测定其分子量。合成的cathelicidin—BF15溶于灭菌水,用于活性检测。
本发明的有益效果在于:
根据金环蛇抗菌肽cathelicidin-BF的氨基酸序列,利用蛋白组学方法设计突变体cathelicidin—BF15,该抗菌肽具有强烈的杀菌作用,对多种临床耐药菌有非常强的杀灭作用,此外具有结构简单,人工合成方便和广谱抗菌等有益特点。
具体实施方式:
下面用实施例来进一步说明本发明的实质性内容,但本发明的内容并不局限于此。
制备cathelicidin-BF15:
I、cathelicidin-BF15的制备方法:根据分离纯化所得金环蛇抗菌肽cathelicidin—BF氨基酸序列,利用蛋白组学方法设计cathelicidin—BF的突变体cathelicidin—BF15。用自动多肽合成仪(433A,Applied Biosystems)合成其全序列,通过HPLC反相柱层析脱盐纯化。
II、分子量测定采用基质辅助激光解析电离飞行时间质谱(MALDI-TOF)。
III、纯化的cathelicidin—BF15用高效液相色谱HPLC方法鉴定其纯度,分子量测定采用基质辅助激光解析电离飞行时间质谱(MALDI-TOF),等电聚焦电泳测定等电点,用自动氨基酸测序仪测定氨基酸序列结构。
cathelicidin-BF15是金环蛇抗菌肽cathelicidin—BF的一种变异体。cathelicidin-BF15是一种直链多肽,含有15个氨基酸残基,分子量1939.47Da,等电点12.05。cathelicidin-BF15全序列为:缬氨酸—赖氨酸—精氨酸—苯丙氨酸—赖氨酸—赖氨酸—苯丙氨酸—苯丙氨酸—精氨酸—赖氨酸—亮氨酸—赖氨酸—赖氨酸—丝氨酸—缬氨酸。
cathelicidin-BF15药理实验:
1.cathelicidin-BF15抗菌活性检测
挑取保存于斜面上的试验菌株均匀涂布于MH固体培养基平板上,将经过灭菌的0.5cm直径的滤纸片置于培养基表面,滴加一定浓度的cathelicidin-BF15样品溶液10μl,于37℃倒置培养18—20小时,观察抑菌圈形成与否。
2.cathelicidin-BF15最小抑菌浓度(Minimum Inhibitory Concentration)测定:
试验菌株接种到MH液体培养基中,37℃振荡培养到对数生长期,用新鲜MH液体培养基稀释到2×105cfu/ml。
在1.9mL培养基中加入经0.22μm孔径膜过滤的一定浓度的cathelicidin—BF15样品0.1mL作为第一管,混匀后取1mL加入第2管,依次倍比稀释,自第9管吸出1mL弃去,第10管系对照管,如表:
表.稀释方法
向各管中加入已稀释好的菌液0.05mL,混匀后放置37℃缓慢振荡培养18小时,于600nm波长处测定光吸收。最小抑菌浓度为看不见细菌生长的最低样品浓度。结果如表1所示。
表1.抗菌活性对比
MIC:最小抑菌浓度,BF:cathlicidin-BF,BF-15:cathlicidin-BF15,Amp:氨苄青霉素,
Ben:注射用青霉素纳,ICS:注射用亚胺培南—西司他丁钠,ND:未检测到活性,-:未实验,IS:临床分离株,DR:氨苄青霉素和青霉素耐药菌株。以上结果为三次独立重复实验平均值。
由表1可见,cathelicidin—BF15对多数试验菌株都具有较强的抗菌活性,尤其是对革兰氏阴性细菌都具有强的杀菌作用,而对大多数革兰氏阳性菌作用不明显。此外,cathelicidin—BF15还具有强的抗真菌活性,对白色念珠菌ATCC2002和毕赤酵母的最小抑菌浓度分别达到18.7μg/ml和9.4μg/ml。
Claims (2)
1、金环蛇抗菌肽cathelicidin—BF变异体cathelicidin—BF15,其特征在于cathelicidin—BF15是一种直链多肽;含有15个氨基酸残基,分子量1939.47Da,等电点12.05;cathelicidin-BF15全序列为:缬氨酸—赖氨酸—精氨酸—苯丙氨酸—赖氨酸—赖氨酸—苯丙氨酸—苯丙氨酸—精氨酸—赖氨酸一亮氨酸—赖氨酸—赖氨酸—丝氨酸—缬氨酸。
2、权利要求1所述的金环蛇抗菌肽cathelicidin—BF变异体cathelicidin—BF15,其特征在于变异体cathelicidin—BF15作为制备广谱抗菌药物的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100589773A CN101386640A (zh) | 2008-09-27 | 2008-09-27 | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100589773A CN101386640A (zh) | 2008-09-27 | 2008-09-27 | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101386640A true CN101386640A (zh) | 2009-03-18 |
Family
ID=40476333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100589773A Pending CN101386640A (zh) | 2008-09-27 | 2008-09-27 | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101386640A (zh) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102294019A (zh) * | 2011-09-07 | 2011-12-28 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF的应用 |
| CN102329375A (zh) * | 2011-09-30 | 2012-01-25 | 中国药科大学 | 一组末端酰胺化的抗菌肽 |
| CN101775067B (zh) * | 2010-02-03 | 2012-11-21 | 中国药科大学 | 一种人工合成的新抗菌肽及其制备方法和应用 |
| CN102940133A (zh) * | 2012-12-12 | 2013-02-27 | 中国科学院昆明动物研究所 | 多肽ca19在制备山羊饲料添加剂中的应用 |
| CN103665111A (zh) * | 2012-09-07 | 2014-03-26 | 山东国际生物科技园发展有限公司 | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 |
| US20140128313A1 (en) * | 2011-04-21 | 2014-05-08 | Barney Bishop | Antimicrobial peptides and uses therefore |
| CN104072583A (zh) * | 2014-05-10 | 2014-10-01 | 冯小荣 | 能抑制和杀灭多种耐药性细菌的多肽 |
| CN104830891A (zh) * | 2015-03-23 | 2015-08-12 | 广东药学院 | 一种金环蛇抗菌肽Cath-BF30的高效制备方法 |
| CN107502981A (zh) * | 2017-08-24 | 2017-12-22 | 海盐派特普科技有限公司 | 一种羽绒服用抗菌防潮羽绒的加工工艺 |
| CN107630363A (zh) * | 2017-08-24 | 2018-01-26 | 海盐派特普科技有限公司 | 一种羽绒服用防虫防霉羽绒 |
| CN107675509A (zh) * | 2017-08-24 | 2018-02-09 | 兰溪市拜瑞珂科技服务有限公司 | 一种抗静电抗菌毛领 |
| CN113321707A (zh) * | 2021-04-05 | 2021-08-31 | 江苏亢钧生物科技有限公司 | 一种人工合成抗菌肽及其应用 |
| CN119912550A (zh) * | 2025-03-31 | 2025-05-02 | 南昌大学第一附属医院 | 一种抗菌肽fp-cath41及其应用 |
-
2008
- 2008-09-27 CN CNA2008100589773A patent/CN101386640A/zh active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101775067B (zh) * | 2010-02-03 | 2012-11-21 | 中国药科大学 | 一种人工合成的新抗菌肽及其制备方法和应用 |
| US20140128313A1 (en) * | 2011-04-21 | 2014-05-08 | Barney Bishop | Antimicrobial peptides and uses therefore |
| US10174081B2 (en) * | 2011-04-21 | 2019-01-08 | George Mason Research Foundation, Inc. | Antimicrobial peptides and uses therefore |
| CN102294019A (zh) * | 2011-09-07 | 2011-12-28 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF的应用 |
| CN102329375A (zh) * | 2011-09-30 | 2012-01-25 | 中国药科大学 | 一组末端酰胺化的抗菌肽 |
| CN103665111B (zh) * | 2012-09-07 | 2016-02-24 | 山东国际生物科技园发展有限公司 | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 |
| CN103665111A (zh) * | 2012-09-07 | 2014-03-26 | 山东国际生物科技园发展有限公司 | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 |
| CN102940133A (zh) * | 2012-12-12 | 2013-02-27 | 中国科学院昆明动物研究所 | 多肽ca19在制备山羊饲料添加剂中的应用 |
| CN104072583A (zh) * | 2014-05-10 | 2014-10-01 | 冯小荣 | 能抑制和杀灭多种耐药性细菌的多肽 |
| CN104830891A (zh) * | 2015-03-23 | 2015-08-12 | 广东药学院 | 一种金环蛇抗菌肽Cath-BF30的高效制备方法 |
| CN107502981A (zh) * | 2017-08-24 | 2017-12-22 | 海盐派特普科技有限公司 | 一种羽绒服用抗菌防潮羽绒的加工工艺 |
| CN107630363A (zh) * | 2017-08-24 | 2018-01-26 | 海盐派特普科技有限公司 | 一种羽绒服用防虫防霉羽绒 |
| CN107675509A (zh) * | 2017-08-24 | 2018-02-09 | 兰溪市拜瑞珂科技服务有限公司 | 一种抗静电抗菌毛领 |
| CN113321707A (zh) * | 2021-04-05 | 2021-08-31 | 江苏亢钧生物科技有限公司 | 一种人工合成抗菌肽及其应用 |
| CN119912550A (zh) * | 2025-03-31 | 2025-05-02 | 南昌大学第一附属医院 | 一种抗菌肽fp-cath41及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101386640A (zh) | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 | |
| CN101412753A (zh) | 金环蛇抗菌肽cathelicidin-BF及其基因和应用 | |
| CN104628829B (zh) | 抗菌肽wy‑21 及其应用 | |
| Van Zoggel et al. | Antitumor and angiostatic peptides from frog skin secretions | |
| CN103665111B (zh) | 一种青环海蛇抗菌肽Hc-CATH的改造体HC-15及其制备方法和应用 | |
| CN106188265A (zh) | 一种抗微生物肽Cm‑CATH2及其基因、制备方法和应用 | |
| CN111658761A (zh) | 天然宿主防御肽Cm-CATH2的应用 | |
| CN102924574A (zh) | 抗菌肽lz1和该抗菌肽在制备抗菌药物中的用途 | |
| CN112625107A (zh) | 一种绿海龟抗菌肽的改造体抗菌肽c-cm8及其制备方法和应用 | |
| CN112625108A (zh) | 一种绿海龟抗菌肽的改造体抗菌肽c-cm5及其制备方法和应用 | |
| CN112625109A (zh) | 一种绿海龟抗菌肽的改造体抗菌肽c-cm6及其制备方法和应用 | |
| CN114983922B (zh) | 生物活性肽与干细胞外泌体在皮肤修复中的应用 | |
| CN1683399A (zh) | 胡蜂抗菌肽及其制备方法和应用 | |
| CN102241748B (zh) | D29分枝杆菌噬菌体来源的pk34多肽及其应用 | |
| CN1927880A (zh) | 无指盘臭蛙抗菌肽及其应用 | |
| CN111518189A (zh) | 一种抗微生物肽MSPiscidin-3、其编码基因及用途 | |
| CN103316327A (zh) | 金环蛇蛇毒抗菌肽在制备抗发炎因子药物中的应用 | |
| CN115746097A (zh) | 抗菌肽as-12w及其制备方法和用途 | |
| CN101845092A (zh) | 家畜驴的一种抗微生物肽Ea-CATH1及其基因和应用 | |
| CN1161377C (zh) | 大蹼铃蟾皮肤肽及其制备方法和在制药中的应用 | |
| CN1142181C (zh) | 大蹼铃蟾多肽在制备抗肿瘤和艾滋病药物中的应用 | |
| CN1064690C (zh) | 鲨鱼软骨血管生成抑制因子及其分离纯化方法 | |
| CN102516382A (zh) | 一种海南湍蛙抗微生物肽Hainanenin-5及其基因、分离纯化、化学合成和应用 | |
| CN114716515A (zh) | 一种多肽类似物及其制备方法和应用 | |
| CN107184953A (zh) | 一种抗菌脂肽皮脂膜修复组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Suzhou Kanger Biomedical Co., Ltd. Assignor: Kuiming Animal Institute of Chinese Academy of Sciences Contract record no.: 2010320000728 Denomination of invention: Variant cathelicidin-BF15 of cathelicidin-BF and use thereof License type: Exclusive License Open date: 20090318 Record date: 20100604 |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090318 |